Edition:
India

argenx NV (ARGX.OQ)

ARGX.OQ on NASDAQ Stock Exchange Global Select Market

24.19USD
17 Nov 2017
Change (% chg)

$-0.15 (-0.62%)
Prev Close
$24.34
Open
$24.32
Day's High
$24.44
Day's Low
$22.21
Volume
5,111
Avg. Vol
4,427
52-wk High
$26.88
52-wk Low
$17.42

Latest Key Developments (Source: Significant Developments)

Argenx launches phase I trial with subcutaneous formulation of ARGX-113​
Monday, 30 Oct 2017 

Oct 30 (Reuters) - ARGENX NV ::‍ARGENX LAUNCHES PHASE I TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113​.‍PHASE I CLINICAL TRIAL WILL ENROLL UP TO 32 HEALTHY VOLUNTEERS​.‍TOPLINE DATA FOR MYASTHENIA GRAVIS AND IMMUNE THROMBOCYTOPENIA EXPECTED IN Q1 AND SECOND HALF OF 2018.‍INTERIM RESULTS FROM PEMPHIGUS VULGARIS TRIAL EXPECTED DURING SECOND HALF OF 2018.​.  Full Article

Argenx 9M total comprehensive loss widens to 16.5 million euros
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - ARGENX NV ::REG-ARGENX REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.9M TOTAL OPERATING INCOME EUR ‍​30.5 MILLION VERSUS EUR 12.5 MILLION YEAR AGO.9M TOTAL COMPREHENSIVE LOSS OF €16.5 MILLION (SEPTEMBER 30, 2016: LOSS €12.6 MILLION).‍​.AS OF SEPT 30 CASH POSITION OF €161.7 MILLION‍​.  Full Article

arGEN X cash position at June end doubles to 108.7 mln euros
Friday, 26 Aug 2016 

arGEN X BV : Q2 revenue is 5.7 million euros ($6.4 million) versus 2.7 million euros year ago . Q2 total operating income is 7.0 million euros versus 4.3 million euros a year ago . Q2 net loss is 7.4 million euros versus loss of 7.0 million euros a year ago . At June 30 cash position of 108.7 million euros (cash, cash-equivalents and financial assets) versus 50.5 million euros a year ago . Phase 2 study in first auto-immune indication planned to start by year-end . Cash position strengthened by $40 million upfront payment from AbbVie and 30 million euros private placement .On ARGX-110 t-cell lymphoma (TCL) - top line date to be presented by end 2016, first combination study to start in H2 2016.  Full Article

ArGEN X announces presentation of updated ARGX-110 phase 1 data in TCL at EHA 2016
Friday, 10 Jun 2016 

ArGEN X Bv :ArGEN X announces presentation of updated ARGX-110 phase 1 data in patients with T-cell lymphoma (TCL) at European Hematology Association (EHA) 2016.  Full Article

ArgenX successfully closes 30 million euro private placement
Friday, 3 Jun 2016 

Argen X Bv : Successfully closes 30 million euro private placement . New shares are expected to be admitted to listing on Euronext Brussels next week .2,703,000 shares have been issued at 11.10 euro ($12.38).  Full Article

arGEN X announces placement of 2.7 mln new shares for 30 mln euros
Wednesday, 1 Jun 2016 

arGEN X BV : Announces private placement of 2,703,000 new shares for an aggregate amount of 30 million euros ($33.37 million) with institutional investors . Issue price per new share in financing is 11.10 euro and represents a discount of 2.6 pct compared to 11.40 euro closing price of arGEN X share on Euronext Brussels on 31 May 2016 .Following completion of transaction, new shares will represent 13.49 pct of total issued shares of arGEN X.  Full Article

arGEN X Q1 net loss stable around 3.0 mln euros
Wednesday, 11 May 2016 

arGEN X BV : Reports Q1 revenue of 2.2 million euros ($2.5 million) versus 1.2 million euros a year ago . Q1 operating loss is 3.0‍​ million euros versus a loss of 3.2 million euros a year ago . Q1 net loss is ‍​3.0 million euros versus a loss of 3.0 million euros a year ago . Cash, cash-equivalents and financial assets at March 31 are 53.8 million euros versus 52.2 million euros a year ago . Expects for ARGX-113 top line phase 1 mad study by end July; announcement phase 2 plan in H2 . Expects for ARGX-111 interim data of phase 1b safety expansion cohort by mid-2016 .Expects for ARGX-110 interim phase 1 study TCL data in Q3 and top line data by end 2016.  Full Article

arGEN X and AbbVie to collaborate on argx-115 against novel immuno-oncology target
Thursday, 21 Apr 2016 

arGEN X BV:RGEN X and AbbVie to collaborate on ARGX-115 against novel immuno-oncology target.  Full Article

arGEN X opens clinical trial sites in South Korea for ARGX-111 program
Thursday, 18 Feb 2016 

arGEN X BV:Opens clinical trial sites in South Korea for ARGX-111 program.  Full Article

arGEN X to list 1,480,420 new shares on Euronext Brussels - Euronext‍​
Wednesday, 20 Jan 2016 

Euronext:arGEN-X BV to list 1,480,420 new shares on Euronext Brussels as of Jan. 21.Reference price for new shares: 10.79 euros.Reason: private placement.  Full Article

BRIEF-Argenx launches phase I trial with subcutaneous formulation of ARGX-113​

* ‍ARGENX LAUNCHES PHASE I TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113​